TherapeuticsMD (NASDAQ:TXMD) had its target price trimmed by Jefferies Financial Group from $4.00 to $3.00 in a research note released on Monday, The Fly reports. The brokerage currently has a hold rating on the stock. Jefferies Financial Group also issued estimates for TherapeuticsMD’s Q2 2019 earnings at ($0.18) EPS, Q3 2019 earnings at ($0.18) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($0.75) EPS, FY2020 earnings at ($0.53) EPS, FY2021 earnings at $0.08 EPS, FY2022 earnings at $1.02 EPS and FY2023 earnings at $1.16 EPS.
A number of other analysts have also recently weighed in on the stock. ValuEngine raised shares of Vermillion from a hold rating to a buy rating in a research report on Wednesday, May 15th. Noble Financial reaffirmed an outperform rating and set a $13.00 price target on shares of TherapeuticsMD in a research report on Tuesday, April 30th. Oppenheimer set a $12.00 price objective on shares of CymaBay Therapeutics and gave the company a buy rating in a research report on Tuesday, June 11th. Cowen decreased their price objective on shares of TherapeuticsMD from $16.00 to $9.00 and set an outperform rating for the company in a research report on Tuesday, June 11th. Finally, BidaskClub raised shares of Winmark from a sell rating to a hold rating in a research report on Tuesday, May 14th. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $9.28.
Shares of TherapeuticsMD stock opened at $2.35 on Monday. The business’s fifty day simple moving average is $2.72. The company has a current ratio of 3.39, a quick ratio of 3.28 and a debt-to-equity ratio of 1.26. TherapeuticsMD has a twelve month low of $2.21 and a twelve month high of $6.94. The stock has a market cap of $590.99 million, a PE ratio of -3.98 and a beta of 1.88.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.01. TherapeuticsMD had a negative net margin of 907.71% and a negative return on equity of 159.71%. The firm had revenue of $3.95 million during the quarter, compared to analysts’ expectations of $5.96 million. During the same period in the prior year, the company earned ($0.11) EPS. The firm’s revenue was up 4.8% on a year-over-year basis. On average, analysts predict that TherapeuticsMD will post -0.67 earnings per share for the current year.
A number of large investors have recently bought and sold shares of the business. FMR LLC boosted its holdings in TherapeuticsMD by 0.5% during the first quarter. FMR LLC now owns 18,178,211 shares of the company’s stock worth $88,527,000 after buying an additional 89,870 shares in the last quarter. Metropolitan Life Insurance Co NY boosted its holdings in TherapeuticsMD by 8.2% during the first quarter. Metropolitan Life Insurance Co NY now owns 60,906 shares of the company’s stock worth $296,000 after buying an additional 4,627 shares in the last quarter. Rubric Capital Management LP boosted its holdings in TherapeuticsMD by 203.6% during the first quarter. Rubric Capital Management LP now owns 4,690,970 shares of the company’s stock worth $22,845,000 after buying an additional 3,145,742 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in TherapeuticsMD by 22.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 87,500 shares of the company’s stock worth $564,000 after buying an additional 16,000 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in TherapeuticsMD by 30.7% during the first quarter. New York State Common Retirement Fund now owns 234,062 shares of the company’s stock worth $1,140,000 after buying an additional 54,962 shares in the last quarter. 78.93% of the stock is owned by institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Recommended Story: The role of implied volatility with call option volume
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.